| Before matching | After matching | ||||
---|---|---|---|---|---|---|
 | END (n = 262) | Non-END (n = 1098) | P | END (n = 261) | Non-END (n = 522) | P |
Age | 65.3 ± 11.8 | 65.1 ± 11.7 | 0.771 | 65.3 ± 11.8 | 64.8 ± 11.8 | 0.593 |
Male sex | 160 (61.1%) | 700 (63.8%) | 0.418 | 159 (60.9%) | 315 (60.3%) | 0.877 |
Hypertension | 213 (81.6%) | 812(74.6%) | 0.017 | 213 (81.6%) | 431 (82.6%) | 0.741 |
Initial NIHSS | 8.0 ± 6.6 | 5.7 ± 6.4 | <0.001 | 7.9 ± 6.6 | 7.6 ± 6.8 | 0.562 |
Discharge NIHSS | 10.4 ± 10.6 | 3.6 ± 5.7 | <0.001 | 10.4 ± 10.5 | 4.8 ± 6.5 | <0.001 |
TOAST | Â | Â | 0.167 | 76 (23.4%) | Â | 0.169 |
 Cardioembolism | 52 (19.8%) | 221 (20.1%) |  | 52 (19.9%) | 111 (21.3%) |  |
 Atherosclerosis | 88 (33.6%) | 328 (29.8%) |  | 88 (33.7%) | 163 (31.2%) |  |
 Small artery disease | 64 (24.4%) | 235 (21.4%) |  | 64 (24.5%) | 102 (19.5%) |  |
 Others | 58 (22.1%) | 314 (28.6%) |  | 57 (21.8%) | 146 (28.0%) |  |
Fasting glucose (mg/dL) | 190.9 ± 84.1 | 184.0 ± 85.5 | 0.238 | 190.7 ± 84.2 | 189.5 ± 87.8 | 0.852 |
Glycated hemoglobin (%) | 7.5 ± 1.7 | 7.3 ± 1.5 | 0.119 | 7.5 ± 1.7 | 7.4 ± 1.6 | 0.392 |
Urine protein positivity | 59 (35.1%) | 143 (21.2%) | <0.001 | 58 (34.7%) | 76 (23.4%) | 0.007 |
Fibrinogen (mg/dL) | 392.9 ± 204.2 | 359.0 ± 119.1 | 0.012 | 392.8 ± 204.6 | 361.1 ± 123.1 | 0.009 |
ESR (mm) | 22.0 ± 20.5 | 21.2 ± 20.1 | 0.547 | 22.0 ± 20.5 | 21.3 ± 18.9 | 0.643 |
CRP (mg/dL) | 0.9 ± 2.3 | 0.9 ± 2.8 | 0.931 | 0.9 ± 2.3 | 1.1 ± 3.2 | 0.528 |
BMI |  |  |  | 24.2 ± 3.3 | 24.5 ± 3.2 | 0.317 |
Metabolic syndrome | 149 (56.9%) | 609 (55.5%) | 0.681 | 149 (57.1%) | 305 (58.4%) | 0.720 |
Lipid panel | Â | Â | Â | Â | Â | Â |
 T.chol (mg/dL) | 179.6 ± 43.2 | 181.7 ± 69.0 | 0.629 | 179.3 ± 43.0 | 182.2 ± 47.4 | 0.396 |
 LDL (mg/dL) | 106.3 ± 37.7 | 106.1 ± 37.4 | 0.919 | 106.0 ± 37.4 | 107.5 ± 38.1 | 0.604 |
 HDL (mg/dL) | 43.7 ± 11.7 | 43.9 ± 15.0 | 0.825 | 43.7 ± 11.7 | 44.0 ± 12.1 | 0.775 |
 TG (mg/dL) | 158.6 ± 113.5 | 163.4 ± 133.4 | 0.600 | 158.7 ± 113.7 | 165.6 ± 153.3 | 0.521 |